加载中...

MedXY News - biomarkers

MedXY AI/MedXY News/Tag: biomarkers

MedXY News

EnglishTag

biomarkers

78 all articles · 20 / page

Ask MedXY AI

clinical trial immunotherapy type 2 diabetes heart failure obesity clinical trials atrial fibrillation Cardiology biomarkers oncology cardiovascular risk public health Hypertension critical care Alzheimer's disease artificial intelligence breast cancer nutrition diabetes cardiovascular disease Pediatrics chronic kidney disease

Latest news

Tag

Continuous Subphenotype Probabilities Expose High-Risk Patients Hidden Within “Hypoinflammatory” Acute Respiratory Failure

Continuous Subphenotype Probabilities Expose High-Risk Patients Hidden Within “Hypoinflammatory” Acute Respiratory Failure

AHRF patients classified as hypoinflammatory are not prognostically uniform. Continuous biomarker-based probabilities reveal substantial mortality heterogeneity, especially below the binary 0.5 threshold, with implications for enrichment st

Section: Critical CareMay 5, 2026

$Neurofilament Light Chain Reveals Rapid Neuroaxonal Injury in New-Onset Refractory Status Epilepticus$

Neurofilament Light Chain Reveals Rapid Neuroaxonal Injury in New-Onset Refractory Status Epilepticus

In a multinational cross-sectional study, serum and CSF neurofilament light chain—unlike S100B—tracked severe acute brain injury in cryptogenic NORSE, rose rapidly over the first 3 weeks, and predicted poor short-term outcome, supporting ur

Section: Critical CareMay 1, 2026

Sex-Specific Differences in P-Tau217 and Tau Aggregation: Implications for Preclinical Alzheimer’s Disease

Sex-Specific Differences in P-Tau217 and Tau Aggregation: Implications for Preclinical Alzheimer’s Disease

Women exhibit higher plasma p-tau217 levels and tau aggregation than men in amyloid-positive individuals, suggesting sex-specific pathways in Alzheimer’s disease progression.

Section: NeurologyMay 1, 2026

Biomarker Signatures in Sepsis: Linking Host Response to Clinical Outcomes

Biomarker Signatures in Sepsis: Linking Host Response to Clinical Outcomes

A prospective cohort study identifies biomarker signatures for host resistance, disease tolerance, and damage in sepsis, revealing associations with mortality and sepsis subtypes.

Section: Critical CareApr 28, 2026

Inflammatory and Cardiac Biomarkers Predict VTE and Bleeding Risks in Cancer Patients

Inflammatory and Cardiac Biomarkers Predict VTE and Bleeding Risks in Cancer Patients

Elevated levels of inflammatory and cardiac biomarkers are linked to higher risks of venous thromboembolism and bleeding in cancer patients, according to a post hoc analysis of the AVERT trial.

Section: CardiologyApr 22, 2026

Precision Blood-Based Diagnostics for Alzheimer’s Disease: The Synergistic Role of Plasma p-tau217 and eMTBR-tau243

Precision Blood-Based Diagnostics for Alzheimer’s Disease: The Synergistic Role of Plasma p-tau217 and eMTBR-tau243

This review synthesizes recent clinical evidence on the integration of plasma p-tau217 and eMTBR-tau243, highlighting how sequential biomarker testing improves the diagnosis of symptomatic Alzheimer’s disease and predicts longitudinal cogni

Section: Clinical UpdatesApr 10, 2026

The Gut-Liver Axis Unveiled: How Microbiome Signatures Track Disease Progression from Fatty Liver to Cancer

The Gut-Liver Axis Unveiled: How Microbiome Signatures Track Disease Progression from Fatty Liver to Cancer

A landmark multicohort study of 1,168 individuals reveals that gut microbiome diversity systematically declines across liver disease stages, with specific bacterial markers like Veillonella and functional metabolic shifts predicting disease

Section: GastroenterologyApr 6, 2026

Decoding the Heart Failure Peptidome: A Cross-Sectional Study Uncovers Novel Biomarkers and Patient Clusters

Decoding the Heart Failure Peptidome: A Cross-Sectional Study Uncovers Novel Biomarkers and Patient Clusters

A groundbreaking mass spectrometry study analyzing 486 heart failure patients and 98 controls identified over 21,000 unique peptides, revealing 1,924 differentially expressed peptides. The research highlights angiotensin-related peptides, n

Section: CardiologyApr 5, 2026

Mid-Regional Pro-Adrenomedullin (MR-proADM): A Superior Prognostic Sentinel in Transthyretin Cardiac Amyloidosis

Mid-Regional Pro-Adrenomedullin (MR-proADM): A Superior Prognostic Sentinel in Transthyretin Cardiac Amyloidosis

This review synthesizes recent evidence identifying MR-proADM as a premier prognostic biomarker in ATTR-CM, demonstrating its ability to outperform traditional natriuretic peptides and enhance existing clinical staging systems.

Section: CardiologyApr 3, 2026

Advancing Venous Thromboembolism Prediction: Insights from Large-Scale Plasma Proteomics and Mendelian Randomization

Advancing Venous Thromboembolism Prediction: Insights from Large-Scale Plasma Proteomics and Mendelian Randomization

This review synthesizes findings from a landmark proteomic study identifying 23 plasma proteins associated with VTE risk, highlighting novel pathways in immunity and vascular senescence while exploring causal links through Mendelian Randomi

Section: CardiologyApr 3, 2026

Beyond the Clot: Novel Proteomic Markers Reveal New Pathophysiological Pathways for Venous Thromboembolism

Beyond the Clot: Novel Proteomic Markers Reveal New Pathophysiological Pathways for Venous Thromboembolism

A large-scale proteomic meta-analysis across five cohorts identified 15 novel plasma protein markers for venous thromboembolism, highlighting the roles of the extracellular matrix, immunity, and vascular senescence in disease risk and offer

Section: CardiologyMar 31, 2026

Beyond the Clot: Novel Proteomic Markers Redefine Venous Thromboembolism Risk

Beyond the Clot: Novel Proteomic Markers Redefine Venous Thromboembolism Risk

This large-scale proteomic analysis identifies 15 novel protein markers for venous thromboembolism, offering new insights into the roles of immunity and extracellular matrix regulation in VTE pathogenesis beyond traditional coagulation path

Section: CardiologyMar 28, 2026

Decoding the Diabetic Heart: Five Unique Proteomic Markers Unveil Heart Failure Risk in Patients with Diabetes

Decoding the Diabetic Heart: Five Unique Proteomic Markers Unveil Heart Failure Risk in Patients with Diabetes

Researchers from the ARIC study have identified five specific proteomic markers that uniquely predict heart failure risk in individuals with diabetes. These findings, including four novel proteins, suggest distinct pathophysiological pathwa

Section: CardiologyMar 26, 2026

Temporal Dynamics of the Circulating Cytokinome in Severe Alcohol-Associated Hepatitis: A Longitudinal Clinical Analysis

Temporal Dynamics of the Circulating Cytokinome in Severe Alcohol-Associated Hepatitis: A Longitudinal Clinical Analysis

This review analyzes the longitudinal kinetics of 43 inflammatory biomarkers in patients with severe alcohol-associated hepatitis, comparing IL-1 receptor antagonism and corticosteroid therapy, highlighting treatment-specific signatures and

Section: Clinical UpdatesMar 28, 2026

Decoding the Diabetic Heart: Novel Proteomic Signatures of Heart Failure Risk in the ARIC Study

Decoding the Diabetic Heart: Novel Proteomic Signatures of Heart Failure Risk in the ARIC Study

A comprehensive review of the ARIC study’s identification of five unique proteomic markers—four novel—that specifically predict heart failure risk in patients with diabetes, offering new insights into lipid metabolism and inflammatory pathw

Section: CardiologyMar 23, 2026

Mapping the Plasma Proteome to Predict Venous Thromboembolism: Evidence from Multi-Cohort Proteomic Profiling and Causal Inference

Mapping the Plasma Proteome to Predict Venous Thromboembolism: Evidence from Multi-Cohort Proteomic Profiling and Causal Inference

This review synthesizes cutting-edge findings from multi-ethnic longitudinal cohorts using high-throughput proteomics to identify novel biomarkers and causal pathways for venous thromboembolism, moving beyond traditional clotting factors.

Section: CardiologyMar 18, 2026

High-Level EBNA-1 Antibodies: A Precise Biomarker for Differentiating Multiple Sclerosis From MOGAD and NMOSD

High-Level EBNA-1 Antibodies: A Precise Biomarker for Differentiating Multiple Sclerosis From MOGAD and NMOSD

A large-scale multicenter study reveals that persistent high-level Epstein-Barr nuclear antigen 1 (EBNA-1) peptide antibody titers serve as a highly specific biomarker, effectively distinguishing Multiple Sclerosis from other neuroinflammat

Section: NeurologyMar 12, 2026

Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease: Leveraging the ‘Natural Stress Test’

Clinical Factors and Biomarkers During Pregnancy and Risk of Cardiovascular Disease: Leveraging the ‘Natural Stress Test’

This review synthesizes findings on how pregnancy biomarkers, particularly sFlt-1 and hs-cTnI, serve as early indicators of long-term maternal cardiovascular risk, offering a unique window for sex-specific prevention.

Section: CardiologyMar 12, 2026

Beyond the Blood-Brain Barrier: Skull Bone Marrow TSPO Overexpression as a Novel Biomarker for Multiple Sclerosis Progression

Beyond the Blood-Brain Barrier: Skull Bone Marrow TSPO Overexpression as a Novel Biomarker for Multiple Sclerosis Progression

**Refining Content Structure** I’m now deeply immersed in the content. I’ve drafted the introduction, designed to capture attention and set the scene. I am expanding on the key findings, including correlations, and the clinical implications

Section: NeurologyMar 10, 2026

Precision Diagnostics in Alzheimer’s Disease: Optimizing Plasma p-tau217 Cutoffs for Patients with Comorbidities

Precision Diagnostics in Alzheimer’s Disease: Optimizing Plasma p-tau217 Cutoffs for Patients with Comorbidities

This review synthesizes evidence on the impact of kidney function, BMI, and anemia on plasma p-tau217 diagnostic accuracy, advocating for subgroup-specific cutoff strategies to improve clinical outcomes.

Section: Clinical UpdatesMar 10, 2026

Prev 1 2 3 4 Next